Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Update and Financial Performance Review

Core Viewpoint - Kymera Therapeutics, Inc. is a biopharmaceutical company focused on developing novel protein degradation therapies, facing competition in the biotech sector, and recently received an "Overweight" rating from Morgan Stanley with a price target increase to $73 [1][5]. Financial Performance - In Q3 2025, Kymera reported a quarterly loss of $0.90 per share, which was worse than the Zacks Consensus Estimate of a $0.71 loss, representing a 26.76% negative surprise [2][5]. - The company's revenue for the same quarter was $2.76 million, missing the Zacks Consensus Estimate by 89.6%, and down from $3.74 million in the same quarter the previous year [3][5]. - Over the past four quarters, Kymera has only exceeded consensus revenue estimates once [3]. Stock Performance - The current stock price of Kymera is $59.91, reflecting a slight increase of 0.32% or $0.19, with fluctuations between $55.66 and $61.30 during the day [4]. - Over the past year, the stock has reached a high of $63.96 and a low of $19.45, with a market capitalization of approximately $4.28 billion [4]. - Today's trading volume for KYMR is 816,036 shares [4].